Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Appeal Against 2021 Cabazitaxel Patent Falls Flat

Executive Summary

An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.

You may also be interested in...



What’s Next? Five Things To Look Out For In September

In the month ahead, Alvogen’s biosimilars sister company Alvotech is anticipated to receive a USFDA decision on its biosimilar Humira candidate, while Hikma’s management will meet investors to discuss prospects for its Generics business.

US Court Revives Jevtana Patent After Mylan Win

A US Court of Appeals has dealt a blow to Mylan by restoring parts of a patent that protects Sanofi’s Jevtana cancer treatment until 2031.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel